SUNRISE, Fla., Jan. 22, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced that Chairman, CTO and CEO, Howard Leonhardt, will present its corporate presentation at the Cell & Gene Therapy Forum 2009 in Washington, D.C., on Tuesday, January 27th at 2:30 p.m.
Leonhardt will be discussing the company's recent progress in its MyoCell(r) clinical trials, its intelligent devices for at-home monitoring of heart patients, and the marketing in Europe of its TGI 1200(tm) cell isolation system, a fully automated cell isolation system that recovers potentially regenerative cells from a patient's own adipose (fat) tissue in about an hour, with minimal operator intervention.
Building on the resounding success of the last Cell & Gene Therapy Forum, the 2009 event will once again provide a highly valuable meeting place for senior-level figures driving the transition of these technologies into safe, commercially viable products. The three-day conference program will feature a mixture of business, regulatory and scientific topics, with speakers drawn from big pharma/biotech, the regulators and cell and gene therapy developers themselves.
This year's Forum will be held at the Grand Hyatt Hotel in Washington, D.C. from January 26th - 28th. More information about the Cell & Gene Therapy Forum is available at http://www.phacilitate.com.
About Bioheart, Inc.
Bioheart, Inc. (Nasdaq:BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(r), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
Forward-Looking Statements:
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof, or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2007, as amended by Amendment No. 1 on Form 10-K/A and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008, June 30, 2008 and September 30, 2008.